Some promising mucosal vaccine candidates are currently being evaluated, and already demonstrate robust boosting of mucosal IgA and T-cell responses to block SARS-CoV-2 transmission and prevent infection upon exposure [48,49,50]. This evidence concerns the gene CD79A and infection.